These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17371531)

  • 1. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
    Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
    Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
    Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
    Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified high-performance liquid chromatographic method to measure both dextromethorphan and proguanil for oxidative phenotyping.
    Hoskins JM; Shenfield GM; Gross AS
    J Chromatogr B Biomed Sci Appl; 1997 Aug; 696(1):81-7. PubMed ID: 9300912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
    Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
    Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6.
    Damkier P; Brøsen K
    Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
    Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
    J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers.
    Hägg S; Spigset O; Dahlqvist R
    Br J Clin Pharmacol; 2001 Feb; 51(2):169-73. PubMed ID: 11259990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19.
    Tamminga WJ; Wemer J; Oosterhuis B; Brakenhoff JP; Gerrits MG; de Zeeuw RA; de Leij LF; Jonkman JH
    Eur J Clin Pharmacol; 2001 May; 57(2):143-6. PubMed ID: 11417446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups.
    Britzi M; Bialer M; Arcavi L; Shachbari A; Kapitulnik T; Soback S
    Ther Drug Monit; 2000 Oct; 22(5):510-6. PubMed ID: 11034254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
    Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
    Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
    Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
    Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
    McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
    J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers.
    Markowitz JS; DeVane CL; Boulton DW; Carson SW; Nahas Z; Risch SC
    Life Sci; 2000 Jan; 66(9):PL133-9. PubMed ID: 10698361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
    Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation.
    Jones DR; Gorski JC; Haehner BD; O'Mara EM; Hall SD
    Clin Pharmacol Ther; 1996 Oct; 60(4):374-84. PubMed ID: 8873685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.
    Eap CB; Bondolfi G; Zullino D; Bryois C; Fuciec M; Savary L; Jonzier-Perey M; Baumann P
    Ther Drug Monit; 2001 Jun; 23(3):228-31. PubMed ID: 11360030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.
    Eap CB; Bender S; Gastpar M; Fischer W; Haarmann C; Powell K; Jonzier-Perey M; Cochard N; Baumann P
    Ther Drug Monit; 2000 Apr; 22(2):209-14. PubMed ID: 10774635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
    Kuhlmann JB; Wensing G; Kuhlmann J
    Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.